Hexstone Capital LLC and its managing member Brendan O'Neil filed a Schedule 13G with the SEC on October 30, 2026, disclosing beneficial ownership of 4,225,352 shares of common stock in Actuate Therapeutics, Inc., representing 7.7% of the company's outstanding shares following the close of a public offering on October 26, 2026.

Key Highlights

  • Reporting persons: Hexstone Capital LLC, a Nevada limited liability company, and Brendan O'Neil, its managing member, filed jointly as a group.
  • Beneficial ownership: Each reporting person reported aggregate beneficial ownership of 4,225,352 shares of common stock, representing 7.7% of the class.
  • Voting and dispositive power: Both Hexstone and O'Neil reported zero sole voting or dispositive power; each reported shared voting and shared dispositive power over 4,225,352 shares.
  • Share count basis: The ownership percentage is based on 54,999,477 shares of common stock outstanding as of October 26, 2026, after giving effect to the closing of the company's public offering.
  • Warrants excluded: Hexstone also holds warrants exercisable for up to 2,112,676 shares, but those shares are excluded from the beneficial ownership count due to a 4.99% beneficial ownership limitation provision in the warrants.
  • Triggering event: The filing was triggered by an event dated October 27, 2026, tied to the closing of an offering disclosed in a prospectus dated October 26, 2026.

Hexstone Capital's Position in Actuate Therapeutics Following October 2026 Offering

According to the filing, Hexstone Capital LLC acquired 4,225,352 shares of common stock of Actuate Therapeutics, Inc. (NASDAQ:ACTU), par value $0.000001 per share, through the company's public offering. The offering was disclosed in a prospectus dated October 26, 2026, related to a registration statement on Form S-1 (File No. 333-299332) declared effective by the SEC on October 26, 2026. The filing reported that 54,999,477 shares of common stock were outstanding as of that date, after giving effect to the offering's closing.

The filing noted that Hexstone also holds warrants exercisable for up to 2,112,676 additional shares of common stock. However, those shares are not counted toward beneficial ownership because the warrants carry a "Blocker" provision prohibiting exercise if doing so would cause Hexstone and its affiliates, together with any persons acting as a group, to beneficially own more than 4.99% of outstanding shares immediately after exercise. As a result, the filing stated, Hexstone's reported beneficial ownership is limited to the 4,225,352 shares of common stock held directly.

Brendan O'Neil, identified as the managing member of Hexstone Capital LLC and a U.S. citizen, does not directly own the shares, according to the filing. "By reason of the provisions of Rule 13d-3 of the Act, Mr. O'Neil may be deemed to beneficially own the Shares which are beneficially owned by Hexstone." Both Hexstone and O'Neil reported shared voting power and shared dispositive power of 4,225,352 shares, with no sole voting or dispositive power held by either party. The principal business address of both reporting persons is listed as 3053 Fillmore St, Suite 303, San Francisco, CA 94123.

What Was Disclosed

Hexstone Capital LLC and Brendan O'Neil filed a Schedule 13G disclosing a combined 7.7% beneficial ownership stake of 4,225,352 shares in Actuate Therapeutics, Inc., acquired through the company's October 2026 public offering, with warrants for an additional 2,112,676 shares excluded due to a 4.99% ownership cap.